FILANA THERAPEUTICS, INC.
FLNAFilana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam (previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How FLNA's past catalysts played out
No drugs found in this phase.
Frequently asked questions
When is FILANA THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for FILANA THERAPEUTICS, INC. (FLNA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FLNA biotech catalysts?→
Add FLNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow FILANA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.